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Background: To evaluate clinicopathological features, radiotherapeutic parameters, and their associations with
responses to radiotherapy (RT) in patients with myeloid sarcoma (MS).
Methods: We reviewed 20 patients receiving RT for MS lesions (in 43 RT courses) and analyzed the patients’
clinicopathologic features and radiotherapeutic parameters, and their associations with complete responses (CR) to
RT using Fisher’s exact test and univariate logistic regression analysis. Generalized Estimating Equation was used to
analyze all 43 irradiated lesions and account for the correlations in RT responses among lesions from the same
patient.
Results: We found that the underlying hematological diseases of the evaluated patients were acute myeloid
leukemia (AML) in 14 patients (70%), chronic myeloid leukemia in 4 patients (20%), myelodysplastic syndrome with
AML transformation in one patient (5%), and de novo MS in one patient (5%). Most patients (55%) received RT for
MS at the time of relapse following bone marrow transplantation (BMT). The most common cytogenetic
abnormality was t(8;21)(q22;q22). The median RT dose of 20 Gy (range 6–35 Gy), administered in 1.5-3.5 Gy
fractions, provided a 63% CR rate. RT dose, sex, cytogenetics, and bone marrow status at the time of RT had no
significant effect on CR. Younger age (<50 y, P = 0.06), BMT prior to RT (P = 0.05), and underlying AML (P = 0.05)
were marginally associated with higher CR to RT.
Conclusions: Our results indicate that a modest RT dose (20-30 Gy) achieves good local control of MS. Age,
previous BMT, and underlying hematologic disease can affect RT response.
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Myeloid sarcoma (MS), also known as granulocytic sar-
coma or chloroma, is a rare clinical condition character-
ized by aggregation of immature myeloid cells presenting
as an extramedullary mass [1]. The most commonly in-
volved sites are the small intestine, bone, skin, and lymph
nodes [2]. MS can develop de novo or emerge during the
clinical course of acute myeloid leukemia (AML), myelo-
proliferative disorder (MPD), or myelodysplastic syndrome
(MDS). In AML patients, MS might represent the first* Correspondence: shkuo101@ntu.edu.tw
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reproduction in any medium, provided the ormanifestation of AML, predating it by months or years. It
can also be the initial presentation of relapse in remission,
with or without underlying bone marrow (BM) relapse,
with reported incidence of 3-9% [3,4].
MS can present at various sites of the body resulting
in prominent symptoms and signs. Diagnosis of MS re-
quires a high degree of vigilance by physicians. Its opti-
mal treatment remains controversial. Chemotherapy or
hematopoietic cell transplantation is often considered
the frontline treatment for MS. Radiotherapy (RT) could
be reserved for palliation of symptomatic or rapidly progres-
sive lesions [5,6] or as part of a combined modality treat-
ment in conjunction with chemotherapy or hematopoietic
cell transplantation. RT is also considered a consolidative
treatment for isolated MS without BM involvement, or
during BM remission after systemic therapy [7]. However,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vious studies are case series reports.
In this study, we investigated the possible underlying
predictive factors, including clinicopathologic features
and radiotherapeutic parameters, for response to RT in
MS patients who received frontline or palliative RT. We
evaluated 20 patients and their irradiated lesions, and
reviewed responses to RT and RT doses reported in pre-
vious studies on MS patients who received frontline or
palliative RT.
Patients and methods
Patients and clinical characteristics
Twenty consecutive patients with MS who received RT
at our institute from 2000 to 2010 were retrospectively
reviewed. This restrospective study was approved by in-
stitutional review board of National Taiwan University
Hospital. Pathologic evaluation of incision biopsy or
needle aspiration of these 20 patients demonstrated
the histomorphologic features of MS characterized by
homogenous malignant infiltrations of immature large
cells with ovale and slightly nuclei. Further immunohisto-
chemical studies, including lysozyme and myeloperoxidase
(MPO), CD68, and chloroacetate, were used to detect
their myeloid origins and exclude lymphoreticular tumors
and mesenchymal tumors. The histopathological charac-
teristics and immunohistochemical results of all tumor
specimens were independently reviewed by experi-
enced hematopathologists. Cytogenetic studies were also
performed. The patients had 43 irradiated lesions. Clin-
icopathologic features including age, sex, underlying
hematologic diseases, MS site for RT, timing of MS
emergence, cytogenetics, and radiotherapeutic param-
eters (including RT dose and fractionation), and responses
of the treated lesions to RT were assessed. During the same
period, 18 MS patients without RT served as control group.
Radiotherapy
RT was provided using 60Cobalt, 6–10 MV linear accel-
erators or 9–12 MeV electrons for superficial lesions.
The RT field was the gross tumor and a 2–3 cm margin.
Radiation doses ranged from 6 Gy to 35 Gy (median,
20 Gy) at a dose per fraction of 1.5-3.5 Gy (median, 2 Gy).
Twenty-eight lesions (65.2%) received RT in doses ≥20 Gy.
Because various fraction sizes were used, conversion of the
total radiation dose to biologically equivalent doses (BED)
delivered at 2 Gy per fraction (BED2) were calculated using
the linear-quadratic model [6]:






 !where n is the number of fractions and d is the dose (Gy)
per fraction. An α/β ratio of 10 is used for leukemia [7],
resulting in a BED2 ranging from 6.5 Gy to 35.9 Gy (me-
dian, 20 Gy).
Lesions’ initial responses to RT were assessed by physical
examination, computed tomography (CT), or magnetic
resonance imaging (MRI) within 4 weeks of completion of
RT. A complete response (CR) was defined as no evidence
of disease and a partial response (PR) as >50% regression
of all measurable tumor mass. Lesions with <50% regres-
sion, stable disease (SD), or progression were classified as
displaying no response.
Statistical analysis
Seven of the 20 patients received multiple courses of RT
to distinct lesions, resulting in 43 irradiated lesions.
Among 7 patients with multiple courses of RT, 2 pa-
tients received coinstantaneous irradiation to multiple
sites and 5 patients received multiple sequential courses
of RT. If a patient received multiple sequential courses
of RT, data from the first RT course were used for ana-
lysis. Data from one RT site with coinstantaneous irradia-
tions were randomly selected when patients concurrently
received RT to multiple sites. Treatment responsesto RT
doses (BED), underlying hematologic diseases, age, sex,
cytogenetics, bone marrow transplant (BMT) prior to RT,
and BM status at the time of RT in MS were correlated.
Fisher’s exact test was used to evaluate the associations
between category variables. Crude odds ratios (OR), 95%
confidence intervals (CI), and P-values were calculated
using univariate logistic regression analysis. Post-RT over-
all survival (OS) was calculated using the Kaplan-Meier
method.
The Generalized Estimating Equation(GEE) was intro-
duced by Zeger and Liang [8] to cope with clustering
data that would otherwise be analyzed using a generalized
linear model. GEE has become an essential tool for the
analysis of correlated data. In this study, GEE was used to
account for correlations in responses to RT among lesions
from the same patient. The unit of analysis was the irradi-
ated lesion. All statistical analysis was performed using
SAS software (9.2, SAS Institute Cary, NC).
Results
Clinicopathologic features and survival of MS patients
with RT
We included 20 patients (median age, 45 years old (y),
range 4–83 y; 10 men and 10 women) with 43 irradiated
lesions in our analyses. The median follow-up time was
4.3 months (range, 0.5-56.7 months). Table 1 displays
the clinicopathologic features of the patients and their
treated lesions. The underlying hematologic diseases in-
cluded AML in 14 (70%) patients, chronic myeloid
leukemia (CML) in 4 (20%) patients, MDS with AML







Timing of GS emergence Cytogenetics
1 62 F AML-M2 Skin Relapse after chemotherapy, BM also (+) Normal
2 50 M CML Anus CML in blast crisis 47 XXY, inv(11)
3 83 M AML-M4 Skin Found at initial presentation with BM (+) t(2;14), NPM(−), FLT3(−)
4 55 M AML-M1 Spinal cord Relapse after chemotherapy, BM also (+) t(9;22) Philadelphia chromosome (+)
5 58 M AML-M1 Skin (7 lesions) Relapse after BMT, BM also (+) Normal
6 6 F CML Bone (right femur) CML in blast crisis t(9;22) Philadelphia chromosome (+)
7 71 F MDS- RAEB 2 Brain - Normal
8 41 F AML-M2 Cervix Relapse after BMT, BM (−) t(8;21)
Right breast Relapse after BMT, BM (−)
9 42 M de novo sarcoma Right nipple Found at presentation, BM (−) Normal
Brain Relapse after chemotherapy, BM also (+)
Paranasosinus Relapse after chemotherapy, BM also (+)
10 56 M CML Spinal cord CML in blast crisis Normal
11 22 M AML-M4 Skin (11 lesions) Relapse after BMT, BM (−) del(1)(p32p36), t(10;11)(p13;q13)
12 44 F CML Right breast CML in blast crisis receiving BMT. relapse after BMT,
BM (−)
Normal
13 75 F AML-M2 Skin Found at initial presentation with BM (+) del(15)(q22q35)
14 29 F AML-M2 Pituitary gland Relapse after BMT, BM (−) Normal
15 32 F AML-M1 Right breast Relapse after BMT, BM (−) Normal
Left breast Relapse after BMT, BM (−)
16 47 M AML-M1 Brain Relapse after chemotherapy, BM also (+) Normal
Spinal cord Relapse after chemotherapy, BM also (+)
17 47 F AML-M2 Skin Relapse after chemotherapy, BM also (+) t(8;21)




19 42 F AML-M1 Right inguinal area Found at initial presentation with BM (+) Normal
20 4 M AML-M2 Bone (left tibia) Relapse after BMT, BM also (+) t(8;21), AML1-ETO fusion transcription (+)
Left buccal mucosa Relapse after BMT, BM also (+)
Bone (right foot) Relapse after BMT, BM also (+)
Abbreviations: AML = acute myeloid leukemia; BM = bone marrow; BMT = bone marrow transplant; CML = chronic myeloid leukemia; FLT3 = FMS-like tyrosine kinase 3; MDS = myelodysplastic syndrome;
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one (5%) patient. Of the 14 AML patients, 6 (42.9%)
were French-American-British (FAB) M2, 5 (35.7%) were
FAB M1, 2 (14.3%) were FAB M4, and one (7.1%) was
FAB M5. The irradiated lesions in the 20 patients in-
cluded 23 (53.5%) skin, 4 (9.3%) breast, 4 (9.3%) brain
parenchyma, 3 (7%) spinal cord, and 3 (7%) bone lesions,
plus one (2.3%) anal, one (2.3%) cervical, one (2.3%) pi-
tuitary, one (2.3%) paranasal sinus, one (2.3%) buccal
mucosal, and one (2.3%) nipple lesion.
In our study, most irradiated MS lesions (17 lesions,
39.5%) were from patients with extramedullary relapse
following BMT, and 10 (23.3%) lesions were from pa-
tients with BM relapse accompanied by extramedullary
relapse. Seven (16.3%) lesions emerged following chemo-
therapy for underlying BM disease. Three (7%) lesions
presented at diagnosis of hematological malignancy with
BM involvement, 3 (7%) lesions presented during CML
blast crisis, one (2.3%) lesion emerged during induction/
consolidation chemotherapy and was persistent after
BMT with positive BM disease, and one (2.3%) lesion
presented as de novo sarcoma as the sole site without
underlying BM disease. Of the 20 patients, 10 (50%) had
normal cytogenetics and 10 (50%) displayed abnormal
chromosomes, among which t(8;21)(q22;q22) was the
most common abnormality (in 3 (30%) of 10 patients).Figure 1 Kaplan-Meier overall survival curve for patients who receiveOther observed abnormal cytogenetics included t(2;14), t
(9;22), and del(15)(q22q35). Three patients displayed
other chromosome complex changes: del(1)(p32p36), t
(10;11)(p13;q13) in one patient, -3p, t(5:17)(q15;q22),
t(11:19)(q23;p13), -17, +19p; der(19)t(17;19)(q11;p11),
t(11;12)(p15;q13) in one patient, and 47 XXY with inv
(11) in one patient.
Of the 20 patients, 9 survived and 11 died. The me-
dian survival time following RT was 6 months (range,
0.5-57 month) in all patients and 6.7 months (range, 2–
57 month) in the surviving patients. The post-RT 1-year
OS was 24% (Figure 1).
Correlations between RT responses and clinical
characteristics
When evaluating the RT responses of the 20 patients
with MS, we identified 13 patients (65%) with CR, 5
(25%) with PR, and 2 (10%) with SD. Totally, 19 (95%)
of 20 patients achieved symptoms relief of MS after RT,
except one patient with SD had persistent symptoms.
Among patients with symptoms relief, 6 patients achieved
symptoms relief during the treatment and 13 patients
achieved symptoms relief within 3 months after comple-
tion of RT. Table 2 displays the correlations between the
patients’ RT responses and their clinical characteristics.
The rate of CR after RT and BED2 (≥22 Gy vs. <22 Gy),d RT (radiotherapy) for MS (post RT survival rate).
Table 2 Predictive factors associated with clinical CR to radiotherapy (n = 20)
Characteristics Complete response
(No. of patients)
Partial response and stable









≥22 Gy 3 4 43% 4.44 0.62-32.07 0.14
<22 Gy 10 3 77% 1 (Referent)
Underlying disease
Non-AML 3 4 43% 4.44 0.62-32.07 0.17
AML 10 3 77% 1 (Referent)
Age
≥50 y 3 5 37.5% 8.33 1.03-67.14 0.06
<50 y 10 2 83.3% 1 (Referent)
Gender
Female 5 4 55.6% 2.13 0.33-13.81 0.64
Male 8 3 72.7% 1 (Referent)
Cytogenetics
Abnormal 6 4 60% 1.56 0.24-9.91 1
Normal 7 3 70% 1 (Referent)
Previous BMT before RT
Yes 6 0 100% NA NA 0.05
No 7 7 50% 1 (Referent)
BM involvement at GS RT
Yes 8 5 61.5% 1.56 0.22-11.37 1
No 5 2 71% 1 (Referent)
Abbreviations: CR, complete remission; PR, partial response; SD, stable disease, BMT, bone marrow transplant; RT, radiotherapy; BM, bone marrow.
*Fisher’s exact test.
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cytogenetics (normal vs abnormal), and BM status at the
time of RT for MS (BM relapse vs BM remission) showed
no significant correlations. Patients younger than 50 years
of age had a marginally higher CR rate than those aged
50 years or older (83.3% vs. 37.6%, P = 0.06). Similarly, pa-
tients receiving BMT prior to RT had a marginally higher
CR rate that those without previous BMT (100% vs. 50%,
P = 0.05).
When using the GEE model to analyze all 43 irradiated
lesions, we observed that BED2, age, sex, cytogenetics,
and bone marrow status at the time of RT for MS
showed no significant associations with CR (Table 3).
Patients with AML had a trend toward higher CR rate
than those with non-AML (OR = 5.436, 95% CI = 0.999-
29.578, P = 0.05). According to the logistic regression
model, BMT prior to RT was also associated with mar-
ginally significant increased rate of CR following RT
(OR = 0.099, 95% CI = 0.0086-1.135, P = 0.06).
Clinicopathologic features and survival of MS patients
without RT
Eighteen MS patients without RT served as control
group. There were 10 (55.6%) men and 8 (44.4%) womenwith a median age of 17 years (range, 1–70 years)
at diagnosis. The underlying hematologic diseases
included AML in 14 (77.8%) patients, CML in 4
(22.2%) patients. The MS lesions included 5 (27.8%)
skin, 4 (22.2%) bone, 2 (11.1%) orbital cavity, 1
(5.6%) brain, 1 (5.6%) breast, 1 (5.6%) cervix, 1 (5.6%)
neck lymph node, 1 (5.6%) oral cavity, 1 (5.6%) ovary, and
1 (5.6%) uterus. Of the 18 patients, 9 (50%) had normal
cytogenetics and 9 (50%) displayed abnormal chromo-
somes, among which t(9;22) (in 4 (22.2%) of 9 patients)
and t(8;21)(q22;q22) (in 2 (11.1%) of 9 patients) were the
common abnormality. Other observed abnormal cytogen-
etics included: t(9;11) in one patient, inv(7)(q22q36) in
one patient, and del(7)(q32q36),del(18)(q21q23) in the
other patient.
Treatments consisted of surgery alone in 1 (5.6%) pa-
tient, chemotherapy alone in 12 (66.4%) patients, a com-
bination of surgery and chemotherapy in 2 (11.2%)
patients, and bone marrow transplantation in 3 (16.8%)
patients. CR was achieved in 16 (88.9%) of 18 patients
and symptom relief was obtained in 17 (94.4%) of 18
patients. Of the 18 patients, 6 survived and 12 died.
The median survival time was 8.5 months (range, 1–
80 month) in all patients and 20.5 months (range, 6–




Partial response and stable









≥22 Gy 6 4 60% 1.15 0.20-6.63 0.88
<22 Gy 21 12 63.64% 1 (Referent)
Underlying disease
Non-AML 3 6 33.33% 5.436 0.999-29.578 0.050
AML 24 10 70.59% 1 (Referent)
Age
≥50 y 9 5 64.29% 2.92 0.47-18.14 0.25
<50 y 18 11 62.07% 1 (Referent)
Gender
Female 7 5 58.33% 1.41 0.31-6.36 0.65
Male 20 11 64.52% 1 (Referent)
Cytogenetics
Abnormal 13 10 56.52% 1.35 0.27-6.83 0.72
Normal 14 6 70% 1 (Referent)
Previous BMT before RT
Yes 16 2 88.89% 0.10 0.01-1.14 0.06
No 11 14 44% 1 (Referent)
BM involvement at GS RT
Yes 16 8 66.67% 1.51 0.23-9.82 0.67
No 11 8 57.89% 1 (Referent)
Abbreviations: CR, complete remission; PR, partial response; SD, stable disease; RT, radiotherapy; BMT, bone marrow transplant; BM, bone marrow.
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was 47.1%.
Discussion
In this study, we evaluated clinicopathological features
and treatment factors and their associations with RT re-
sponses in 20 patients with MS (in 43 RT courses), and
also summarizes the clinicopathological features, cyto-
genetics, involved sites of MS, timing of RT, RT doses
and fractions, and RT responses in published case re-
ports (summarized in Table 4). Although our patients
showed similar clinicopathologic features to those previ-
ously reported, we identified other diversified sites of MS
involvement, including the breast [9-11], brain and spinal
cord [12-15], cervix [16-19], paranasal sinus [20,21], and
oral cavity [22,23]. We also observed previously unre-
ported sites of involvement such as the nipple in men and
the pituitary. Although the mechanism of MS formation is
not fully understood, the leukemic cells homing to specific
sites might be related to blast neural cell adhesion mole-
cules (CD56) [2]. For example, high neural cell adhesion
molecule expression in breast, testicular, ovarian, and gut
tissue could explain these specific regions being common
sites of MS involvement [24].In our cytogenetically abnormal patients, t(8;21)(q22;
q22) was the most common cytogenetic change [48].
Limited previous reports exist on our identified cytogen-
etic abnormalities of t(2;14), t(9;22), and del(15)(q22q35)
[11]. Systemic treatment outcome might be distinct
among different cytogenetic groups. For example, in the
study by Rollig et al., patients with t(8;21)(q22;q22) had
good outcome following systemic treatment [49]. In our
study, most patients had underlying AML disease. Of
the non-AML patients, most had CML and a few had de
novo sarcoma and MDS. In GEE analysis, we observed a
trend that AML patients displayed higher CR rates than
non-AML patients, which suggested that the underlying
tumor behavior and biology of MS resulting from under-
lying diseases might differ. Further investigation to
evaluate the radiobiological effects and elucidate the dif-
ferential radiosensitivities of MS resulting from each
underlying hematologic disease is warranted.
Another of our study findings was that BMT prior to
RT resulted in marginally significant improvement of the
CR rate in MS patients; however, the precise mechanism
for the differential effects of RT on MS pre- and post-
BMT are not well-understood. The incidence of patients
developing MS after BMT is reportedly 0.2%-3.7%
Table 4 Published case reports on radiotherapy for GS
Study Patient
no.





Lee et al. [25] 1 50 t(9;22)(q34;q11) CML Relapse after BMT, BM (−) Clavicle and manubrium 15 Gy CR
Taverna et al. [26] 1 62 - AML-M4 Relapse after
chemotherapy, BM also
(+)
Left gluteal and the
deeper pelvic muscles
20 Gy/10fx PR
Au et al. [27] 1 24 del( 5)(q13; q33) AML-M0 Relapse after BMT, BM (−) Left breast 30 Gy PD
Pulsoni et al. [28] 1 84 - De novo sarcoma At presentation, BM (−) Skin 90 Gy/8fx CR
Kasahara et al. [29] 1 47 der (1; 7)(q10; p 10) Idiopathic myelofibrosis
and de novo sarcoma
At presentation, BM (−) Right submandibular
tumor
30 Gy CR
Buckland et al. [30] 1 35 Normal karyotype De novo sarcoma At presentation, BM (−) C4-6 spine 32 Gy/16fx CR
Lee at al. [31] 1 43 - De novo sarcoma At presentation, BM (−) Maxillary gingiva 36 Gy CR
Fleckenstein et al. [32] 1 73 Normal karyotype AML Found at initial




Cozzi et al. [33] 1 39 Philadelphia positive CML Chronic phase Left shoulder 21 Gy PD
Nishimura et al. [34] 1 30 Add(3)(q27), t(8;21)(q22,
q22)
AML-M2 Relapse after BMT, BM (−) Right frontal intra/
extracranial tumor
16 Gy CR
Pelosini et al. [35] 1 25 t(8,21)with AML1-ETO
expression.
AML-M0 Relapse after BMT, BM (−) Left leg 40 Gy CR
Rosenberg et al. [36] 1 8 del(7)(q22;q36),t(7;11)(p15;
p15)





Pitz et al. [37] 1 50 Normal karyotype AML Relapse after
chemotherapy, BM also
(+)
Uterus/ endometrium 30 Gy/10fx CR
Kumar et al. [38] 1 10 - De novo sarcoma At presentation, BM (−) Left orbit 24 Gy/12fx CR
Vassiliou et al. [39] 1 40 - De novo sarcoma At presentation, BM (−) Mediastinal lymph node 41.4 Gy/23fx CR
Kozelj et al. [40] 1 52 t(8;21) AML At presentation, BM (+) Heart 15 Gy/10fx CR
Lee et al. [41] 1 25 45,X,-Y,del(2)(q21q31),t
(5;11)(q31;q13),t(8;21)(q22;
q22),t(10;19)(q22;q13.1)
De novo sarcoma At presentation, BM (−) Orbit 70 Gy PR




20 Gy/10fx Good PR
Verra et al. [43] 1 45 inv(16) AML-M4 Relapse after BMT, BM (−) L4 to S3 spine 21 Gy/7fx PR
Antic et al. [44] 1 24 Normal karyotype De novo sarcoma At presentation, BM (−) Lumbosacral spine 40 Gy/20fx CR
Mignano et al. [45] 1 20 - AML-M2 Relapse after BMT, BM (−) Left jaw 30 Gy/15fx CR
Heart 24 Gy/12fx CR

















Table 4 Published case reports on radiotherapy for GS (Continued)
Alvarez et al. [46] 1 41 CBFβ/MYH11 fusion and
inv(16) (p13q22)






Masetti et al. [47] 1 11 11q23 rearrangement
(MLL-AF10)




L1 to S3 Epidural mass 20 Gy/16fx Good PR at the
end of RT
Chak et al. [5] 33 (54
courses of
radiotherapy)
1.5 - 8 1 - 28 (84.8%) acute non-
lymphocytic leukemia, 11
(15.2%) chronic leukiemia
- 33% bone, 31% soft
tissue, 11% lymph node,
7% spinal cord, 6% brain,
11% other sites
(Mediastinal mass, 2;
pelvic mass, 1; pleural












- AML 19 (86%), MDS 2
(9%), Isolated Chloroma
1 (5%)




39% head and neck, 24%
extremity, 9% spine, 9%
brain, 6% genito-urinary,
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often include high-dose busulfan/cyclophosphamide or
cyclophosphamide in combination with total body irradi-
ation. In allogeneic BMT, graft versus host interaction is
an important factor in determining the success or tox-
icity of the transplant. Preclinical studies have demon-
strated that radiation is involved in the recruitment of
effector CD8+ T cells to nonlymphoid tissues and this
effect enhances the graft-versus-leukemia (GVL) effect
after allogeneic transplantation [53,54]. These findings
may explain that the more favorable response of MS to-
ward RT after bone marrow transplant might be resulted
from RT-inducing GVL effect. The influences of marked
immununological disturbance during transplantation and
graft versus host/leukemia interaction on the effects of RT
(which is highly dependent on immunological interactions
among the tumor, normal cells, and tumor microenviron-
ment) warrant further investigation.
Age is considered a prognostic factor in AML. In our
study, patients younger than 50 years of age had a trend
toward higher CR rates following RT than those aged
50 years or older (83.3% vs 37.6%, P = 0.06). Kantarjian
et al. reported reduced anthracycline sensitivity and Ras,
Src, and tumor necrosis factor pathway activation in
older patients with AML [55]. These deregulated signal-
ing pathway variations may explain the poor response to
RT in older patients with MS.
Although RT generally yields high CR rate, the optimal
dose for MS has yet to be determined. Chak et al. [5] in-
vestigated the relationship between RT dose and re-
sponse in 33 MS patients (54 RT courses), observing
that the CR rate was closely associated with RT dose
(CR rate: <10 Gy, 18%; 10–19.99 Gy, 43%; 20–29.99 Gy,
86%; >30 Gy, 89%). In their study on 22 patients with
MS (33 RT courses) who received a median dose of 20 Gy
(range 6–36 Gy) in fractions of 1.5-4 Gy, Bakst et al.
showed that RT resulted in excellent disease control and
minimal morbidity [9]. The authors recommended a low-
dose regimen of 24 Gy in 12 fractions to irradiate MS.
Our findings are consistent with the two mentioned large
series reports, and demonstrate excellent local control in
our 20 MS patients (43 RT courses), who received a me-
dian dose of 20 Gy (range 6–35 Gy) in fractions of 1.5-
3.5 Gy. Although our results indicated that BED2 had
nonsignificant effects on CR rate (≥22 Gy vs <22 Gy), most
previous cases series have reported good local control of
MS in low to moderate RT doses between 20 Gy and
30 Gy (Table 4). The main mechanism of radiation damage
to leukemic cells is apoptosis. For high-dose irradiation,
the D0 of p53-deficient HL-60 leukemic cells is 2.2 Gy, and
the D0 of p53 wild MOLT-4 leukemic cells is 0.87 Gy [56].
According to radiobiological and clinical data, a 20–30 Gy
radiation dose might be sufficient to achieve good local
control for MS [57].Conclusion
In summary, in this study, we evaluated the clinicopath-
ological features and radiotherapeutic responses of 20
MS patients with 43 lesions, and identified unusual sites
of MS presentation, including the nipple in men and the
pituitary. Diversified cytogenetic abnormalities can occur
in MS; however, the most common MS-associated cyto-
genetic change is t(8;21)(q22;q22). We further identified
that the CR rate is optimal using moderate RT doses be-
tween 20 Gy and 30 Gy with conventional fractionation.
Younger age, BMT prior to RT, and AML patients had
marginally significant trend toward higher CR rate in MS.
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